Company intelligence / Profile preview

Proxygen

Ownership: Private
Employees: ~75
Development stage: Preclinical

Overview

Proxygen has developed a proprietary platform for discovering molecular glue degraders that can target previously undruggable proteins. The company has made significant progress in both internal drug discovery and strategic partnerships with major pharmaceutical companies. No clinical results have been published as of May 2025; programs are preclinical but advancing toward the clinic[3].

Therapeutic areas: Oncology
Modalities: Molecular glue degraders (small molecules)
Industry: Biotech

Drug pipeline

1 asset

PXG-CycK

Preclinical

Partnerships

Boehringer IngelheimMerck KGaAMerck & Co., Inc. (MSD outside US/Canada)

Beyond the preview

Go deeper on Proxygen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proxygen.

Explore the full profile